Axsome Therapeutics (MIL:1AXSM) Short Interest


MIL:1AXSM Axsome Therapeutics Inc MIL:1AXSM
31 GF Score
Price €214.70
GF Value €177.26
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


MIL:1AXSM vs MDGL, IONS, BMRN: Short Interest Comparison

For the Biotechnology subindustry, Axsome Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Short Interest falls into.


MIL:1AXSM
31GF Score
Axsome Therapeutics Inc MIL:1AXSM
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Axsome Therapeutics (MIL:1AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of €214.70 is trading 21.1% above its estimated GF Value™ of €177.26. GuruFocus considers Axsome Therapeutics to be Modestly Overvalued.

Key valuation signals for MIL:1AXSM:

  • Short Interest:
  • GF Value™: €177.26 vs. price of €214.70 (21.1% above fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the MIL:1AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Axsome Therapeutics Business Description

Other Exchanges AXSM:USA0HKF:UK19X:Germany
Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
31GF Score

Get the complete analysis for MIL:1AXSM

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€214.70
Price
€177.26
GF Value